Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Ono Pharmaceutical Co., Ltd.
Age
15–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects \< 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is ≥ 18 years of age
Completely removed melanoma by surgery performed within 12 weeks of randomization
Stage IIIb/C or Stage IV before complete resection
No previous anti-cancer treatment
You may not be if
Ocular or uveal melanoma
History of carcinomatosis meningitis
History of auto-immune disease
Treatment directed against the resected melanoma that is administrated after the surgery
Clareo Health | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
